VANCOUVER, Canada

Nada Lallous

USPTO Granted Patents = 1 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Nada Lallous

Introduction

Nada Lallous is an accomplished inventor based in Vancouver, Canada. She has made significant contributions to the field of cancer therapeutics through her innovative research and development of Myc-Max inhibitor compounds. Her work aims to provide new treatment options for various types of cancer, showcasing her dedication to improving patient outcomes.

Latest Patents

Nada Lallous holds a patent for her invention titled "Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith." This patent includes Myc-Max inhibitory compounds that have the potential to treat several cancers, including prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma, and myeloid leukaemia. She has 1 patent that reflects her innovative approach to cancer treatment.

Career Highlights

Nada Lallous is affiliated with the University of British Columbia, where she conducts her research. Her work is characterized by a strong focus on developing therapeutic strategies that target specific cancer pathways. This focus has positioned her as a key figure in the ongoing fight against cancer.

Collaborations

Nada collaborates with esteemed colleagues, including Artem Tcherkassov and Paul S Rennie. These partnerships enhance her research efforts and contribute to the advancement of cancer therapeutics.

Conclusion

Nada Lallous is a pioneering inventor whose work in Myc-Max inhibitor compounds represents a significant advancement in cancer treatment. Her dedication to research and collaboration continues to inspire progress in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…